References:

• Tan, D.X.; Hardeland, R.; Back, K.; Manchester, L.C.; Alatorre-Jimenez, M.A.; Reiter, R.J. (2016). On the significance of an alternate pathway of melatonin synthesis via 5-methoxytryptamine: Comparisons across species. J. Pineal Res. 61, 27–40.
• Stehle JH, Saade A,  Rawashdeh O,  Ackermann K,  Jilg A,  Sebestény T,  Maronde E. (2011). A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res . 51:17–43.
• Roopin M, Levy O. (2012). Temporal and histological evaluation of melatonin patterns in a ‘basal’ metazoan. J Pineal Res 2012; 53:259–269.
• Lerner AB, Case JD, Takahashi Y. (1985). Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc; 80:2587
• Chen Y, Tain Y, Sheen J, Huang L. (2012). Melatonin utility in neonates and children. Journal of the Formosan Medical Association. 111, 57-66
• Byeon Y, Park S, Kim YS, Park DH, Lee S, Back K. Light-regulated melatonin biosynthesis in rice during the senescence process in detached leaves. J Pineal Res. 2012 Aug;53(1):107-11. doi: 10.1111/j.1600-079X.2012.00976.x. Epub 2012 Jan 31. PMID: 22289080.
• Hardeland, R.; Madrid, J.A.; Tan, D.X.; Reiter, R.J. (2012) Melatonin, the circadian multioscillator system, and health: The need fordetailed analyses of peripheral melatonin signaling. J. Pineal Res. 52, 139–166.
• Sun X, Deng J, Liu T, Borjigin J. (2002). Circadian 5-HT production regulated by adrenergic signaling. Proc Natl Acad Sci U S A.: 99: 4686-4691.
• Radogna F, Diederich M, Ghibellui L. (2010). Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol. 80:1844-52
• Reiter RJ, Tan DX, Osuna C, Gitto E. (2000). Action of melatonin in the reduction of oxidative stress. A review. J Biomed Sci. 7:444-58.
• Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-perumal SR. (2011) Melatonin – a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 93: 350-384.
• Espino J, Pariente JA, Rodríguez AB. (2011). Role of melatonin on diabetes related metabolic disorders. World J Diabetes. 2: 82-91.
• Bubenik GA. (2008). Thirty-four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol. 59 Suppl 2: 33-51.
• Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, García-Mauriño S, et al. (2004). Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J. 18: 537-539.
• Meng H, Yan WY, Lei YH, Wan Z, Hou YY, Sun LK, Zhou JP. (2019). SIRT3 regulation of mitochondrial quality control in neurodegenerative diseases. Front. Aging Neurosci. 11,313.
• Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B. (2017). Melatonin as a mitochondria-trageted antioxidant: One of evaluation best ideas. Cell Mol. Life Sci. 74, 3863-3881.
• Galano A, Tan DX, Reiter RJ. (2013). On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal Res. 54, 245-257.
• Mesri Alamdari, N.; Mahdavi, R.; Roshanravan, N.; Lotfi Yaghin, N.; Ostadrahimi, A.R.; Faramarzi, E. (2015). A double-blind, placebo controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm. Metab. Res. 47, 504–508.
• Shah, S.A.; Khan, M.; Jo, M.H.; Jo, M.G.; Amin, F.U.; Kim, M.O. (2017). Melatonin stimulates the SIRT1/Nrf2 signaling pathway counteracting lipopolysaccharide (LPS)-induced oxidative stress to rescue postnatal rat brain. CNS Neurosci. Ther. 23, 33–44.
• Moniruzzaman, M.; Ghosal, I.; Das, D.; Chakraborty, S.B. (2018). Melatonin ameliorates H2O2-induced oxidative stress through modulation of Erk/Akt/NFkB pathway. Biol. Res. 51, 17.
• Hermoso, D.; Shimada, L.; Gilglioni, E.; Constantin, J.; Mito, M.; Hermoso, A.; Salgueiro-Pagadigorria, C.; Iwamoto, E. (2016).  Melatonin protects female rats against steatosis and liver oxidative stress induced by oestrogen deficiency. Life Sci. 157, 178–186.
• Maiocchi, S.L.; Morris, J.C.; Rees, M.D.; Thomas, S.R. (2017).Regulation of the nitric oxide oxidase activity of myeloperoxidase by pharmacological agents. Biochem. Pharmacol. 135, 90–115.
• Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, et al. (2004).  Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 36: 1-9.
• Reiter, R.J.; Tan, D.X.; Korkmaz, A.; Rosales-Corral, S.A. (2014). Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum. Reprod. Update 20, 293–307.
• Choi, Y.; Nakamura, Y.; Akazawa, N.; Park, I.; Kwak, H.B.; Tokuyama, K.; Maeda, S. (2021). Effects of nocturnal light exposure on circadian rhythm and energy metabolism in healthy adults: A randomized crossover trial. Chronobiol. Int. 1–11.
• Hong, F.; Pan, S.; Xu, P.; Xue, T.;Wang, J.; Guo, Y.; Jia, L.; Qiao, X.; Li, L.; Zhai, Y. (2020).  Melatonin orchestrates lipid homeostasis through the hepatointestinal circadian clock and microbiota during constant light exposure. Cells 9, 489.
• Yoshiuchi, I. (2021). Analysis of evolution and ethnic diversity at glucose-associated SNPs of circadian clock-related loci with cryptochrome 1, cryptochrome 2, and melatonin receptor 1B. Biochem. Genet. 59, 1173–1184.
• Pivonello, C.; Negri, M.; Patalano, R.; Amatrudo, F.; Montò, T.; Liccardi, A.; Graziadio, C.; Muscogiuri, G.; Pivonello, R.; Colao, A. (2021). The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. Obes. Rev. e13390.
• Prado, N.; Ferder, L.; Manucha, W.; Diez, E. (2018). Anti-inflammatory effects of melatonin in obesity and hypertension. Curr. Hypertens. Rep. 20, 45.
• Yawoot, N.; Govitrapong, P.; Tocharus, C.; Tocharus, J. (2021).  Ischemic stroke, obesity, and the anti-inflammatory role of melatonin. Biofactors, 47, 41–58.
• Kireev RA, Tresguerres AC, Garcia C, Ariznavarreta C, Vara E, Tresguerres JA. (2008).  Melatonin is able to prevent the liver of old castrated female rats from oxidative and pro-inflammatory damage. J Pineal Res. 45:394–402. doi: 10.1111/j.1600-079X.2008.00606.x
• Cuesta S, Kireev R, García C, Forman K, Escames G, Vara E, et al. (2011).  Beneficialeffect of melatonin treatment on inflammation, apoptosis and oxidative stress on pancreas of a senescence accelerated mice model.Mech Ageing Dev. 132:573–82. doi: 10.1016/j.mad.2011.10.005.
• Ma, N.; Zhang, J.; Reiter, R.J.; Ma, X. (2020). Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation. Med. Res. Rev. 40, 606–632.
• Radogna F, Diederich M, Ghibelli L. (2010).  Melatonin: a pleiotropic molecule regulating inflammation. Biochem pharmacol. 80: 1844-1825.
• Zisapel N. (2018).  New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 175(16):3190–3199.
•  Damiani JM, Sweet BV, Sohoni P. (2014).  Melatonin: an option for managing sleep disorders in children with autism spectrum disorder. Am J Health-Syst Pharm. 71:95–101.
• Kunz D, Mahlberg R. (2010).  A two-part, double-blind, placebocontrolled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 19:591–596.
• Karasek M. (2004).  Melatonin, human aging, and aged-related diseases. Exp Gerontol. 2004; 39 (11-12): 1723-1729.
• Lahteenmaki R, Puustinen J, Vahlberg T, et al. (2014). Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebocontrolled trial. Br J Clin Pharmacol. 77:975–985.
• Arroll MA, Wilder L, Neil J. (2014). Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 13: 91.
• Yoshida K, Hashimoto T, Sakai Y, Hashiramoto A. (2014)Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis. J Immunol Res: 282495.
• Lin L, Huang QX, Yang SS, Chu J, Wang JZ, et al. (2013) Melatonin in Alzheimer’s disease. Int J Mol Sci 14: 14575-14593.
• Lin GJ, Huang SH, Chen SJ, Wang CH, Chang DM, et al. (2013) Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci 14: 11742-11766.
• Reiter RJ, Tan D, Paredes SD, Fuentes-Broto L. (2010).  Beneficial effects of melatonin in cardiovascular disease. Annals of Medicines. 42: 276–285.
• Da Silva DG, Ricci O Jr, de Almeida EA, Bonini-Domingos CR. (2015). Potential utility of melatonin as an antioxidant therapy in the management of sickle cell anemia. J Pineal Res 58: 178-188.
• Espino J, Pariente JA, Rodríguez AB (2011) Role of melatonin on diabetes related metabolic disorders. World J Diabetes 2: 82-91.
• Hardeland R (2012) Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 3: 194-225.
• Pirozzi FF, Bonini-Domingos CR, Ruiz MA. (2015).  Metabolic Actions of Melatonin on Obesity and Diabetes: A Light in the Darkness. Cell Biol: Res Ther, 4:2.
• Cipolla-Neto J, Amaral FG, Afeche SC , Tan DX, Reiter RJ. (2014).  Melatonin, energy metabolism, and obesity: a review. J. Pineal Res. 56:371–381.
• Mendes C, Lopes AM, do Amaral FG, Peliciari-Garcia RA, Turati Ade O, et al. (2013) Adaptations of the aging animal to exercise: role of daily supplementation with melatonin. J Pineal Res 55: 229-239.
• Reiter RJ. (1991). Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12, 151-180.
• Robera, R.; Kirilov, G.; Tomova, A.; Kumanov, P. (2008). Melatonin-insulin interactions in patients with metabolic syndrome. J. Pineal Res. 44, 52–56.
• Plano, S.A.; Casiraghi, L.P.; GarciaMoro, P.; Paladino, N.; Golombek, D.A.; Chiesa, J.J.  (2017). Circadian and metabolic effects of light: Implications in weight homeostasis and health. Front. Neurol. 8, 558.
• Klein DC, Moore RY. (1979). Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res.  Oct 5;174(2):245-62.
• Reiter RJ. (1991). Melatonin: the chemical expression of darkness. Mol Cell Endocrinol. 79: C153-158.
• Lockley SW, Brainard GC, Czelsler CA. (2003). High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab; 88:4502–4505.
• GOOLEY JJ, RAJARATNAM SM, BRAINARD GC et al. (2010). Spectral responses of the human circadian system depend on the irradiance and duration of exposure to light. Sci Transl Med; 2:31–33.
• SAHIN L, FIGUEIRO MG. (2013). Alerting effects of short-wavelength (blue) and long-wavelength (red) lights in the afternoon. Physiol Behav ; 117:1–7.
• Arends J. Melatonin and the mammalian pineal gland. (1998). Chapmann and Hall.London. pp. 201-285.
• Genario R, Cipolla-Neto J, Bueno AA, Santos HO.(2020). Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications Pharmacol Res. 2021 Jan;163:105254. doi: 10.1016/j.phrs.2020.105254. Epub  Oct 17.
• Simonneaux V, Ribelayga C. (2003). Generation of the melatonin endocrine message in mammals: A Review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacological Review. 55, 325-395.
• Barrenetxe J, Delagrange P, Martínez JA. (2004). Physiological and metabolic functions of melatonin. J Physiol Biochem. Mar;60(1):61-72. doi: 10.1007/BF03168221.
• PARDRIDGE WM, MIETUS LJ. (1980). Transport of albumin-bound melatonin through the blood-brain barrier. J Neurochem; 34:1761–1763.
• MORIN D, SIMON N, DEPRES-BRUMMER P et al. (1997). Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum. Pharmacology; 54:271–275.
• Arendt J, Skene DJ. (2005). Melatonin as a chronobiotic. Sleep Med Rev. 9(1):25-39.
• Harderland R, Poeggeler B. (2001).  Non- vertebrate melatonin. J pineal Res. 30: 65-74.
• Skene D, Papagiannidou E, Hashemi E, Snelling J, Lewis D, Fernández M, Ioannides C. (2001). Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. Journal of Pineal research; 31(4): 333-342.
•  Lynchr HJ, Wurtmanm J, Moskowitzm  A, Archerand   C, Ho (1975). Daily Rhythm in Human Urinary Melatonin. Science. 187(4172): 169-171.
• Hardeland R. (2010). Melatonin metabolism in the central nervous system. Curr Neuropharmacol. 8(3):168-81. doi: 10.2174/157015910792246244.
• Morgan PJ, Barrett P, Howell HE, Helliwell R. (1994). Melatonin receptors: localization, molecular pharmacology and physiological significance. Neuochemistry international. 24(2): 101-146.
• Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. (2016).MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annual review of pharmacology and toxicology. 56: 361-383.
• Dubocovich  ML, Markowska  (2005). Functional MT1 and MT2 melatonin receptors in mammals. Endocrine ; 27:101–110.
• Dubocovich   ML, Delagrange    P, Krause  DN et al. (2010). International Union of Basic and Clinical Pharmacology. LXXV. nomenclature, classification, and pharmacology of g protein-coupled melatonin receptors. Pharmacol Rev; 62:343–380.
• Afeche    SC, Amaral   FG, Villela   DCM et al. (2008).  Melatoninand the Pineal Gland. In: New Research on Neurosecretory Systems. ROMANO E, DE LS, ed., Nova Biomedical Books,New York, pp. 151–177.
• Sadowsky DW, Yellon S, Mitchell MD, Nathanielsz PW. (1991). Lack of effect of melatonin on myometrial electromyographic activity in the pregnant sheep at 138-142 days gestation (term= 147 days gestation). Endocrinology. 182:1812-1818.
• Borjigin J, Zhang LS, Calinescu AA (2012). Circadian regulation of pineal gland rhythmicity. Mol Cell Endocrinol 349: 13-19.
• Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, et al. (2000). Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 275: 31311-31317.
• De Farias TDSM, Cruz MM, de Sa RCDC, Severi I, Perugini J, Senzacqua M, Cerutti SM, Giordano A, Cinti S, Alonso-Vale MIC. (2019) Melatonin Supplementation Decreases Hypertrophic Obesity and Inflammation Induced by High-Fat Diet in Mice. Front Endocrinol (Lausanne). Nov 5;10:750. doi: 10.3389/fendo.2019.00750
• Shao M, Vishvanath L, Busbuso NC, Hepler C, Shan B, Sharma AX, et al. (2018). De novo adipocyte differentiation from Pdgfrb. Nat Commun. 9:890. doi: 10.1038/s41467-018-03196-x.
• Donohoe, F.; Wilkinson, M.; Baxter, E.; Brennan, D.J.  (2020). Mitogen-activated protein kinase (MAPK) and obesity-related cancer. Int. J.Mol. Sci., 21, 1241.
• Longo, S.; Bollani, L.; Decembrino, L.; Di Comite, A.; Angelini, M.; Stronati, M. (2013). Short-term and long-term sequelae in intrauterine growth retardation (IUGR). J. Matern. Fetal Neonatal. Med. 26, 222–225.
• Genario, R.; Cipolla-Neto, J.; Bueno, A.A.; Santos, H.O. (2021). Melatonin supplementation in the management of obesity and obesityassociated disorders: A review of physiological mechanisms and clinical applications. Pharmacol. Res. 163, 105254.
• Labib M. (2003) acp Best Practice No 168. The investigation and management of obesity. J Clin Pathol., 56, 17-25.
• Saarela S, Reiter RJ. (1994). Function of melatonin in thermoregulatory processes. 54(5):295-311. doi: 10.1016/0024-3205(94)00786-1.
• Mellado C, Rodríguez V, de Diego JG, Alvarez E, Blázquez E (1989). Effect of pinealectomy on liver insulin and glugagon receptor concentrations in the rats. J Pineal Res 6: 77-88.
• Jimenez-Aranda A, Fernandez-Vazquez G, Campos D (2013). Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. J Pineal Res 55: 416-423.
• Helmaier G. and Hoffmann K. (1974). Melatonin stimulates growth of brown adipose tissue. Nature 247(5438): 224-225.
•  Brzezinska – slebodzinska E . Slebodzinska  B  . Styczynska   E^.. (1998) Stimulatory effect of melatonin on the 5'-monodeiodinase activity in the liver, kidney, and brown adipose tissue during the early neonatal period of the rabbit. Journal of pineal research. 24(3), 137-141 ; 1-4.
• Fernández Vázquez G, Reiter RJ, Agil A. (2018) Melatonin increases brown adipose tissue mass and function in Zücker diabetic fatty rats: implications for obesity control. Journal of pineal research. 64(4)e12472.
• de Souza CAP, Gallo CC, de Camargo LS, de Carvalho PVV, Olesçuck IF, Macedo F, da Cunha FM, Cipolla-Neto J, do Amaral FG. (2019) Melatonin multiple effects on brown adipose tissue molecular machinery. Journal of pineal research.;66(2):e12549.
• Townesnd KL, Tseng YH. ( 2014) Brown fat fuel utilization and thermogenesis. Trends Endocrinol Metab; 25: 168-177.
• Stanford KI, Middelbeek RJ, Townsend KL et al. (2013). Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest ; 123: 215-223.
• Richard D, Picard F. (2011). Brown fat biology and thermogenesis. Front Biosci; 16: 1233-1260. 
• Yang, W.; Tang, K.; Wang, Y.; Zhang, Y.; Zan, L. (2017). Melatonin promotes triacylglycerol accumulation via MT2 receptor during differentiation in bovine intramuscular preadipocytes . Sci. Rep. 7, 15080.
• Lv, D.; Tan, T.; Zhu, T.; Wang, J.; Zhang, S.; Zhang, L.; Hu, X.; Liu, G.; Xing, Y. (2019).   Leptin mediates the effects of melatonin on female reproduction in mammals. J. Pineal Res. 66, e12559.
• Suriagandhi, V.; Nachiappan, V. (2021). Protective effects of melatonin against obesity-induced by leptin resistance. Behav. Brain Res.417, 113598.
• Buonfiglio, D.; Tchio, C.; Furigo, I.; Donato, J.; Baba, K.; Cipolla-Neto, J.; Tosini, G. (2019). Removing melatonin receptor type 1 signaling leads to selective leptin resistance in the arcuate nucleus. Pineal Res. 67, e12580.
• Szewczyk-Golec KAW, Reiter RJ. (2015) Inter- relationships of the chronbiotic, melatonin, with leptin and adiponectin: implications for obesity. Journal of Pineal research. 59(3):277-291.
• Kedziora-Komatowska K, Szewczyk-Golec K, Kozakiewicz M, Pawluk H, Czuczejko J, et al. (2009) Melatonin improve oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res 46: 333-33.
• Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, Casteilla L, Pénicaud L. (2003) Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology.;144(12):5347-52.
• Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ. (2011). Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev. 12:167-188.
• Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, Rasmussen DD. (2000). Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat Endocrinology. Feb;141(2):487-97.
• Tamura I. Tamura H. Kawamoto-Jozaki M. Doi-Tanaka Y. Takagi H. Shirafuta Y. Mihara Y. Maekawa R. Taketani T. Sato S. et al. (2021). Long-term melatonin treatment attenuates body weight gain with aging in female mice. J. Endocrinol. 251: 15–25.
• Wang L. McFadden JW. Yang G. Zhu H. Lian H. Fu T. Sun Y. Gao T. Li M. (2021). Effect of melatonin on visceral fat deposition, lipid metabolism and hepatic lipo-metabolic gene expression in male rats. J. Anim. Physiol. Anim. Nutr., 105: 787–796.
• Tung YT. Chiang PC. Chen YL. Chien YW. (2020). Effects of melatonin on lipid metabolism and circulating irisin in Sprague-Dawley rats with diet-induced obesity. Molecules 25: 3329.
• Xu PF. Wang JL. Hong, F. Wang S. Jin X. Xue TT. Jia L. Zhai YG. (2017) Melatonin prevents obesity through modulation of gut microbiota in mice. J. Pineal Res. 62, e12399.
• Farias T. Paixao RID. Cruz MM. de Sa R. Simão JJ. Antraco VJ. Alonso-Vale MIC. (2019) Melatonin supplementation attenuates the pro-inflammatory adipokines expression in visceral fat from obese mice induced by a high-fat diet. Cells .8, 1041.
• Onaolapo AY. Adebisi EO. Adeleye AE. Olofinnade AT. Onaolapo OJ. (2020) Dietary melatonin protects against behavioural, metabolic, oxidative, and organ morphological changes in mice that are fed high-fat, high- sugar diet. Endocr. Metab. Immune. Disord. Drug Targets, 20: 570–583.
• Terron MP. Delgado-Adamez J. Pariente JA. Barriga C. Paredes SD. Rodriguez A. (2013) Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats. Physiol Behav 118:8-13.
• Jiménez-Aranda A, Fernández-Vázquez G, Campos D, Tassi M, Velasco-Perez L, Tan DX, Reiter RJ, Agil A. (2013). Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. J Pineal Res. 55(4):416-423.
• Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD. (2007) Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. 32:284-288.
• Halpern B, Mancini MC, Bueno C, Barcelos IP, de Melo ME, Lima MS, Carneiro CG, Sapienza MT, Buchpiguel CA, do Amaral FG, Cipolla-Neto J. (2019) Melatonin Increases Brown Adipose Tissue Volume and Activity in Patients With Melatonin Deficiency: A Proof-of-Concept Study. Diabetes, 68(5): 947-952.
• Amstrup AK, Sikjaer T, Pedersen SB, Heickendorff L, Mosekilde L, Rejnmark L. (2016) Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial. Clinical Endocrinology. 84(3):342-347.
• Walecka-Kapica E, Klupińska G, Chojnacki J, Tomaszewska-Warda K, Błońska A, Chojnacki C. (2014) The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women. Prz Menopauzalny. 13(6):334-338.
• Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. (1999) Maternal and development toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci. 50:271-279.
• Sadowsky D, Yellon S, Mitchell M, Nathanielsz P. (1991) Lack of effect of melatonin on myometrial electromyographic activity in the pregnant sheep at 138-142 days gestation (term = 147 days gestation). Endocrinology. 128:1812-1818.
• Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. (2016) The Safety of Melatonin in Humans. Clinical drug investigation. 36(3): 169-175.
• Seabra ML, Bignotto M, Pinto LR Jr, Tufik S. (2000) Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. 49(4): 193-200.
• Wei S, Smits M, Tang X, Kuang L, Meng H, Ni S, Xiao M, Zhou X. (2020) Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials. Sleep Medicine 68:1-8.
• Gordon N. (2000) The therapeutics of melatonin: a paediatric perspective. Brain Dev. 22:213-217.
• Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. (2005) Melatonin for sleep disturbances in Parkinson's disease . Sleep Med. Sep;6(5):459-66.
• Labay LM, Kraner JC, Mock AR, Sozio TJ. (2019) The Importance of Melatonin Detection in Pediatric Deaths. Acad Forensic Pathol. 9(1-2):24-32.

Shimomura E, Alice JB, Gordon C, Warren W, Jackson GF. (2019) Case report of sudden death in a